Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

InMed Pharmaceuticals Inc.

NASDAQ: MTRI · Life Sciences · 12 alerts · CIK 1728328

Share price
$19.87Close, Nov 16
Market cap
$109M
Shares outstanding
5.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All InMed Pharmaceuticals Inc. filings on SEC EDGAR ↗

7:03 AM ET 8-K
M&A Deal

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.

Counterparty
Mentari Therapeutics, Inc.
4:46 PM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.

Value
$490M
Counterparty
Mentari Therapeutics, Inc.
8:18 PM ET Form 4
Insider Buying

InMed Pharmaceuticals Insider ADAR1 Capital Management LLC Buys $34.6K of Stock

ADAR1 Capital Management LLC bought 2,640 shares of InMed Pharmaceuticals Inc. at $13.10 a share, worth $34.6K in total on Nov 5, 2026. Shares held after the trade: 98,297 (+2.8%).

Value
$34.6K
Shares
2,640
Price
$13.10
Holding change
+2.8%
Trade date
Nov 5, 2026
8:05 AM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.

Value
$490M
Counterparty
InMed Pharmaceuticals Inc.
8:08 AM ET 8-K
Reverse Stock Split

InMed Pharmaceuticals Reverse Stock Split

InMed Pharmaceuticals completed a 1-for-10 reverse stock split (consolidation), reducing its outstanding shares from approximately 5.49 million to 549,374. The company also legally changed its name to Mentari Therapeutics, Inc. and confirmed shareholder approval of all matters at its 2026 Annual General and Special Meeting.

6:06 AM ET 8-K
Reverse Stock Split

InMed Pharmaceuticals Reverse Stock Split

InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed a 1-for-10 reverse stock split (consolidation) of its common shares effective November 4, 2026. The split reduced the outstanding share count from approximately 5.49 million to 0.55 million shares to facilitate its pending merger and reorganization with Mentari Therapeutics, Inc. (Delaware).

4:47 PM ET 8-K
M&A Deal

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals provided a status update on its pending merger with Mentari Therapeutics, which is expected to close in Q4 2026. Mentari has announced private placements totaling $490 million to support operations through 2029, and InMed shareholders will vote on the transaction at a meeting on November 4, 2026.

Counterparty
Mentari Therapeutics, Inc.

“We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026. Our focus remains on completing the transaction, which we believe provides shareholders with an opportunity to participate in the development of Mentari's migraine prevention pipeline.”

Eric A. Adams, InMed President and CEO
6:03 AM ET 10-Q
Financial Results

InMed Pharmaceuticals Q1 2026 Results: Net Loss of $2.33M, Loss Widens

InMed Pharmaceuticals Inc. reported its financial results for the quarter ended September 30, 2026, highlighting ongoing research and development expenses related to its cannabinoid-based pipeline. The company continues to manage its cash position to fund clinical trials and proprietary manufacturing technology development.

Key figure
Net loss $2.33M
4:39 PM ET Form 4
Insider Buying

InMed Pharmaceuticals Insider ADAR1 Capital Management LLC Buys $10.7K of Stock

ADAR1 Capital Management LLC bought 8,021 shares of InMed Pharmaceuticals Inc. at $1.33 a share, worth $10.7K in total on Oct 14, 2026. Shares held after the trade: 954,509 (+0.8%).

Value
$10.7K
Shares
8,021
Price
$1.33
Holding change
+0.8%
Trade date
Oct 14, 2026
5:12 PM ET Form 4
Insider Buying

InMed Pharmaceuticals Insider ADAR1 Capital Management LLC Buys $57.1K of Stock

ADAR1 Capital Management LLC bought 42,920 shares of InMed Pharmaceuticals Inc. at $1.33 to $1.33 a share (average $1.33) in 3 transactions, worth $57.1K in total between Oct 1, 2026 and Oct 5, 2026. Shares held after the trade: 935,021 (+2.0%).

Value
$57.1K
Shares
42,920
Average price
$1.33
Holding change
+2.0%
Trade date
Oct 1, 2026 to Oct 5, 2026
5:12 PM ET 8-K
Nasdaq/NYSE Compliance Notice

InMed Pharmaceuticals Nasdaq/NYSE Compliance Notice

InMed Pharmaceuticals received a deficiency notice from Nasdaq for failing to maintain the minimum $2.5 million shareholders' equity requirement for continued listing. The company reported shareholders' equity of $1,075,007, largely due to expenses related to its pending merger with Mentari Therapeutics. InMed expects to regain compliance upon the closing of the merger, which is anticipated to bring approximately $490 million in gross proceeds to the combined company.

Counterparty
The Nasdaq Stock Market LLC
Term
45 days to submit plan

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.